During the last forty years we have witnessed impressive advances in the field of antiviral
drug discovery culminating with the introduction of therapies able to stop human …

Drug resistance is prevalent across many diseases, rendering therapies ineffective with
severe financial and health consequences. Rather than accepting resistance after the fact …

Proteolysis targeting chimera (PROTAC) degradation of pathogenic proteins by hijacking of
the ubiquitin-proteasome-system has become a promising strategy in drug design. The …

The successful development of antiviral drugs is highly dependent on a close interaction
and collaboration between the chemist and the biologist (biomedic). This is illustrated by a …

Annual and sporadic influenza outbreaks pose a great threat to human health and the
economy worldwide. Moreover, the frequent mutation of influenza viruses caused by antigen …

The human immunodeficiency virus (HIVa) has now been established as the causative
agent of the acquired immunodeficiency syndrome (AIDS) for over 20 years. 1, 2 During this …

The prevalence of chronic viral infectious diseases, such as human immunodeficiency virus
(HIV), hepatitis C virus (HCV), and influenza virus; the emergence and re-emergence of new …

Hepatitis B virus (HBV) infection is a prime cause of liver diseases such as hepatitis,
cirrhosis and hepatocellular carcinoma. The current drugs clinically available are nucleot (s) …

The evolution of drug resistance is one of the most fundamental problems in medicine. In
HIV/AIDS, the rapid emergence of drug‐resistant HIV‐1 variants is a major obstacle to …

A decade ago, just five drugs were licensed for the treatment of viral infections. Since then,
greater understanding of viral life cycles, prompted in particular by the need to combat …